IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tempel, R.
Right arrow Articles by Heffron, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tempel, R.
Right arrow Articles by Heffron, F.
Infection and Immunity, September 2006, p. 5095-5105, Vol. 74, No. 9
0019-9567/06/$08.00+0     doi:10.1128/IAI.00598-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Attenuated Francisella novicida Transposon Mutants Protect Mice against Wild-Type Challenge

Rebecca Tempel,{dagger}* Xin-He Lai,{dagger} Lidia Crosa, Briana Kozlowicz, and Fred Heffron

Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon

Received 12 April 2006/ Returned for modification 17 May 2006/ Accepted 5 June 2006

Francisella tularensis is the bacterial pathogen that causes tularemia in humans and a number of animals. To date, there is no approved vaccine for this widespread and life-threatening disease. The goal of this study was to identify F. tularensis mutants that can be used in the development of a live attenuated vaccine. We screened F. novicida transposon mutants to identify mutants that exhibited reduced growth in mouse macrophages, as these cells are the preferred host cells of Francisella and an essential component of the innate immune system. This approach yielded 16 F. novicida mutants that were 100-fold more attenuated for virulence in a mouse model than the wild-type parental strain. These mutants were then tested to determine their abilities to protect mice against challenge with high doses of wild-type bacteria. Five of the 16 attenuated mutants (with mutations corresponding to dsbB, FTT0742, pdpB, fumA, and carB in the F. tularensis SCHU S4 strain) provided mice with protection against challenge with high doses (>8 x 105 CFU) of wild-type F. novicida. We believe that these findings will be of use in the design of a vaccine against tularemia.


* Corresponding author. Mailing address: 6543 Basic Sciences Addition/CROET Building, Department of Molecular Microbiology and Immunology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239. Phone: (503) 494-6841. Fax: (503) 494-6862. E-mail: tempelr{at}ohsu.edu.

Editor: J. T. Barbieri

{dagger} R.T. and X.-H.L. contributed equally to this work.


Infection and Immunity, September 2006, p. 5095-5105, Vol. 74, No. 9
0019-9567/06/$08.00+0     doi:10.1128/IAI.00598-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2006 by the American Society for Microbiology. All rights reserved.